Brief: Theseus Pharmaceuticals Announces FDA Clearance Of Investigational New Drug Application For THE-630
01/11/2021 11:04
Nov 1 (Reuters) - Theseus Pharmaceuticals Inc THRX.O :
* THESEUS PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR THE-630, A PAN-VARIANT
KIT INHIBITOR IN DEVELOPMENT FOR THE TREATMENT OF
GASTROINTESTINAL STROMAL TUMORS (GIST)
* THESEUS PHARMACEUTICALS - PLANS TO INITIATE A PHASE 1/2
DOSE
ESCALATION AND EXPANSION CLINICAL TRIAL OF THE-630 BETWEEN LATE
Q4 2021 AND MID-Q1 2022
Source text for Eikon: ID:nPn6hThP4a
Further company coverage: THRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theseus Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
Theseus Pharma rises as Concentra Biosciences agrees to take it private
Brief: Theseus Pharmaceuticals To Be Acquired by Concentra Biosciences
Brief: Theseus Pharmaceuticals Inc Says As Part Of A Reduction In Workforce, Co Terminated Employment Of Timothy P. Clackson, Co's CEO, Effective As Of Dec 7